Epidemiology and costs associated with genital warts in Canada

Marra, Fawziah; Ogilvie, Gina; Colley, Lindsey; Kliewer, Erich V.; Marra, Carlo

doi:10.1136/sti.2008.030999

Cited by 59 publications

(80 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The average cost of treatment per episode was $C190 translating to estimated annual, direct medical costs in BC of approximately $C1 million. (30) Similar estimates of AGW prevalence (130 per 100 000) are reported in the United Kingdom, where AGW is a reportable disease. (31) Estimates from the US are slightly higher, between 150 and 205 per 100 000 in privately-insured populations.…”

Section: Risk Factors For Hpv In Malessupporting

confidence: 61%

“…Marra et al present additional data with respect to burden of illness and costs. (30) Both studies report a significant burden of AGW disease with incidence rates of 154 per 100 000 in men and 120 per 100 000 in women (Manitoba, 2004) and 131 per 100 000 in men and 121 per 100 000 in women (BC, 2006). Prevalence estimates were also comparable at 146.4/100 000 (165.2/100 000 for men and 128.4/100 000 for women) in Manitoba on December 31, 2004 and 148/100 000 (157 per 100 000 in men and 140 per 100 000 in women) in BC on December 31, 2006.…”

Section: Risk Factors For Hpv In Malesmentioning

confidence: 99%

“…Two recent publications provide important baseline data in terms of the epidemiology of AGW in Canada. Both Kleiwer et al (29) and Marra et al (30) link population-based hospital and physician databases to estimate the incidence and prevalence of AGW, in Manitoba and BC respectively. Marra et al present additional data with respect to burden of illness and costs.…”

Section: Risk Factors For Hpv In Malesmentioning

confidence: 99%

“…(29,30) • The impact of vaccinating males, compared to that of improving vaccination uptake in existing female cohorts or vaccinating additional female cohorts.…”

Section: Hpv Vaccine (Hpv2 or Hpv4) Is Not Recommended In Females <9 mentioning

confidence: 99%

See 3 more Smart Citations

Update on Human Papillomavirus (HPV) Vaccines

Dm¹,

Mt²,

Ds³

2012

Canada Communicable Disease Report

View full text Add to dashboard Cite

Section: Risk Factors For Hpv In Malessupporting

confidence: 61%

Section: Risk Factors For Hpv In Malesmentioning

confidence: 99%

Section: Risk Factors For Hpv In Malesmentioning

confidence: 99%

“…(29,30) • The impact of vaccinating males, compared to that of improving vaccination uptake in existing female cohorts or vaccinating additional female cohorts.…”

Section: Hpv Vaccine (Hpv2 or Hpv4) Is Not Recommended In Females <9 mentioning

confidence: 99%

See 2 more Smart Citations

Update on Human Papillomavirus (HPV) Vaccines

Dm¹,

Mt²,

Ds³

2012

Canada Communicable Disease Report

View full text Add to dashboard Cite

“…Warts don't represent a problem in terms of mortality but are associated with clinical symptoms such as bruising, pain and bleeding and are mainly caused by genotypes 6 and 11 [52,45,44]. It is estimated that warts represent the result of only a fraction of HPV infections and populations studies showed a prevalence of 0.6-1.5 up to 4-13 % in relation to sexual behavior [48,56,15].…”

Section: Related Pathologiesmentioning

confidence: 99%

Human papillomavirus (HPV) infection: a Mozambique overview

2016

View full text Add to dashboard Cite

Human Papillomavirus is agent of the most common sexually transmitted disease which is able to infect mucosal and cutaneous membranes of the anogenital region, upper aerodigestive tract, and other head and neck mucosal regions. Although mainly HPV infection can be asymptomatic and transient, it may persist and give rise to various lesions such as warts, condyloma dysplasia and cancers depending on low or high risk type of HPV infection. Moreover, growing recent evidence suggests a role of this virus in male and female fertility. To date no effective prevention, test, treatment and control strategies are provided for people in developing countries despite the reported high incidence of HPV both in women and men. This paper reviews the more recent literature about HPV infection highlighting epidemiology, related pathologies and possible fertility effects of HPV in male and female with particular attention to the Mozambique context.

show abstract

The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada

Steben

Ouhoummane

Rodier

et al. 2017

Journal of Medical Virology

View full text Add to dashboard Cite

In Québec province in Canada, a public school-based and catch-up HPV vaccination programs with the quadrivalent vaccine have been introduced in September 2008 for girls aged 9-17 years. We assessed the early impact of the HPV vaccination program on the incidence of anogenital warts (AGW) in the Quebec general population. We used the provincial health administrative data of the Régie de l'assurance maladie du Québec (RAMQ). AGW were identified either through a prescription of podofilox, or a medical procedure code specific to AGW, or a diagnostic code for viral warts followed by a prescription of imiquimod or fluorouracil. Sex- and age-specific incidence rates were calculated for pre-vaccination (2004-2007) and vaccination (2009-2012) periods. We found a significant decline of 45% and 19% in the incidence of AGWs among females aged 15-19 and 20-24 years, respectively. A decline of 21% was also seen among males aged 15-19 years. The median age at an episode of AGW increased from 27 years in 2004 to 31 years in 2012 among females and remained stable in males. Our findings indicate that the HPV public vaccination program is associated with an important reduction in the incidence of AGW among young females and males. The benefit is more pronounced among females 15-19 years of age, who were eligible for the public vaccination program. The observed decline among young males could be due to herd immunity and/or privately paid vaccination.

show abstract

Epidemiology and costs associated with genital warts in Canada

Abstract: AGW are associated with a significant burden of illness and costs to the healthcare system.

Cited by 59 publications

References 21 publications

Update on Human Papillomavirus (HPV) Vaccines

Update on Human Papillomavirus (HPV) Vaccines

Human papillomavirus (HPV) infection: a Mozambique overview

The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada

Contact Info

Product

Resources

About